+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06813976

Phase 3 Trial Comparing Modified FOLFIRINOX to Capecitabine or Gemcitabine as Additional Chemotherapy After Surgery for Ampullary Adenocarcinoma

Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-07-11

294

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Ampullary adenocarcinoma is a rare type of digestive cancer that affects the ampulla of Vater. Surgery is currently the only curative option, but about 4% of patients experience cancer recurrence within 2 years after surgery. This phase 3 trial is studying two chemotherapy approaches given after surgery to reduce the chance of cancer returning. The study compares a new combination treatment called modified FOLFIRINOX mFOLFIRINOX against standard treatments with either capecitabine or gemcitabine. Participants will be randomly assigned to one of two groups. Group A will receive mFOLFIRINOX every two weeks for 12 cycles 24 weeks, consisting of oxaliplatin, irinotecan, 5-fluorouracil, and folinic acid. Group B will receive either capecitabine or gemcitabine chosen by the investigator, administered over 24 weeks in specified schedules. Quality of life questionnaires and biological assessments will be conducted before and during treatment. Additional exams will occur every three months. During the study, participants will undergo regular evaluations including scans, lab tests, and questionnaires to monitor their health and treatment effects. Disease-free survival will be assessed for up to 36 months to measure how long patients remain free of cancer recurrence. Safety and treatment responses will be closely followed throughout treatment and after completion. The total time in the study includes treatment and follow-up periods extending over several years.

CONDITIONS

Brief Title

PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma

Research Team

G

Gaël ROTH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here